Cited by 166Tuberculosis Research and EpidemiologyInfectious Diseases and TuberculosisPharmaceutical Economics and Policy

The DOI matches its Crossref record.

Approval of Novel TB Drug Celebrated—With Restraint

Cohen, Jon·2013·Science

DOI 10.1126/science.339.6116.130

Open this paper in CoChat — free account

Abstract

On New Year's Eve, the U.S. Food and Drug Administration approved the first new tuberculosis drug in more than 40 years.

Integrity signals

Registry

Crossref · 10.1126/science.339.6116.130

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 101–166 of 166

Advances in Drug Discovery and Development for Pediatric Tuberculosis
Hoagland, D. T., Zhao, Y., & Lee, R. E., Jr. (2016) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150722101723 · Cited by 15
Quinolones for mycobacterial infections
Rubinstein, E., & Keynan, Y. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.03.005 · Cited by 12
TB trifusion antigen adsorbed on calcium phosphate nanoparticles stimulates strong cellular immunity in mice
Amini, Y., Moradi, B., Tafaghodi, M., et al. (2016) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-016-0326-y · Cited by 12
“In addition, only two new chemical drugs have been approved for use in treatment of MDR-TB patients in four decades [4,5].”
Background
Making the case: developing innovative adherence solutions for the treatment of tuberculosis
Verma, M., Furin, J. J., Langer, R., & Traverso, G. (2019) · BMJ Global Health · doi:10.1136/bmjgh-2018-001323 · Cited by 12
“10 Considering that bedaquiline is the first new approved TB drug in more than 40 years and the dearth of others in the TB drug development pipeline to overcome challenges of the current drugs, nanotechnology can provide an enormous impact with design of novel and targeted delivery systems for existing drugs.(11) Idea…”
Structure and assembly of the MmpL5/MmpS5 efflux transporter from Mycobacterium tuberculosis
Xiong, Z., Yang, X., Wang, S., Smart, C. J., Sisson, H. M., Lin, Z., Hu, T., Ran, Y., Xu, C., Yang, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60365-5 · Cited by 13
First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug
Pieren, M., Gutiérrez-Solana, A. A., Arbos, R. M. A., et al. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae107 · Cited by 11
Emerging drugs and drug targets against tuberculosis
Lambert, N., Abdalla, A. E., Duan, X., & Xie, J. (2016) · Journal of drug targeting · doi:10.1080/1061186x.2016.1258705 · Cited by 11
“tuberculosis remain poorly understood [46].”
Design, synthesis and antimycobacterial activity of new benzothiazinones inspired by rifampicin/rifapentine
Wang, A., Lu, Y., Lv, K., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104135 · Cited by 11
Synthesis, anti-mycobacterial and cytotoxic evaluation of substituted isoindoline-1,3-dione-4-aminoquinolines coupled via alkyl/amide linkers
Rani, A., Viljoen, A. J., Johansen, M. D., et al. (2019) · RSC Advances · doi:10.1039/c8ra10532d · Cited by 10
Antitubercular drugs: possible role of natural products acting as antituberculosis medication in overcoming drug resistance and drug-induced hepatotoxicity
Rana, H. K., Singh, A. K., Kumar, R., & Pandey, A. K. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02679-z · Cited by 10
“In the last decade new drugs (bedaquiline and delamanid) have been approved for TB treatment (Gler et al. 2012; Cohen 2013).”
Refined homology model of cytochrome bcc complex B subunit for virtual screening of potential anti-tuberculosis agents
Pan, Z., Wang, Y., Gu, X., et al. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1688196 · Cited by 10
Synthesis and evaluation of pyridine-derived bedaquiline analogues containing modifications at the A-ring subunit
Barbaro, L., Nagalingam, G., Triccas, J. A., Tan, L., West, N. P., Baell, J. B., & Priebbenow, D. L. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00063b · Cited by 11
MmpR5 protein truncation and bedaquiline resistance in Mycobacterium tuberculosis isolates from South Africa: a genomic analysis
Roberts, L. W., Malone, K. M., Hunt, M., et al. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(24)00053-3 · Cited by 9
Microwave Assisted Synthesis of Disubstituted Imidazo[1,2-a]pyridine-3-carboxylic Acid Esters
Liu, M., Zhang, Q., Li, L., Wu, Z., Li, Z., & Guo, H. (2015) · Heterocycles · doi:10.3987/com-15-13299 · Cited by 9
e-Pharmacophore model-guided design of potential DprE1 inhibitors: synthesis, in vitro antitubercular assay and molecular modelling studies
Kumar, A., Rajappan, R., Kini, S. G., et al. (2021) · Chemical Papers · doi:10.1007/s11696-021-01743-3 · Cited by 9
“Bedaquiline, pretomanid and delamanid are the only drugs approved by the FDA (Food and Drug Administration) in the last four decades to treat MDR-TB which highlights the associated challenges in the field of antitubercular drug discovery (Cohen 2013).”
Background
Benzylsulfanyl benzo-heterocycle amides and hydrazones as new agents against drug-susceptible and resistant Mycobacterium tuberculosis
Lu, X., Hu, X., Liu, Z., et al. (2017) · MedChemComm · doi:10.1039/c7md00146k · Cited by 9
Furoxan derivatives demonstrated in vivo efficacy by reducing Mycobacterium tuberculosis to undetectable levels in a mouse model of infection
de Souza, P. C., Fernandes, G., Marino, L. B., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110592 · Cited by 9
Contribution of telacebec to novel drug regimens in a murine tuberculosis model
Komm, O. D., Tyagi, S. K., Garcia, A. J., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00962-24 · Cited by 8
In vitro bioevaluation and docking study of dihydrosphingosine and ethambutol analogues against sensitive and multi-drug resistant Mycobacterium tuberculosis
Linhares, L. D. A., Peixoto, A. D. S., de Sousa, L. D. Â. C., Laet, J. P. D. L., Santos, A. C. D. S., Pereira, V. R. A., Neves, M. M. C., Ferreira, L. F., Hernandes, M. Z., de la Vega, J., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115579 · Cited by 9
Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting
Catho, G., Couraud, S., Grard, S., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.12.022 · Cited by 8
Design, synthesis, anti‐mycobacterial and cytotoxic evaluation of C‐4 functionalized 1,8‐naphthalimide‐heterocyclic hydrazide conjugates
Shalini, S., Johansen, M. D., Kremer, L., et al. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13503 · Cited by 8
“…in 2012 and by European Medicine Agency in 2014, with some countries having already started using them as shorter regimens for TB treatment (Cohen, 2013; Ryan & Lo, 2014).12 However, the nature of Mtb to become latent and resistant to available drugs has highlighted TB as a global health…”
BackgroundMethod
Synthesis, Characterization, and Antimicrobial Activity Screening of Some Novel 3-(2-(3-(Substituted benzyloxy)oxetan-3-yl)-3-fluorophenoxy)-8-fluoro-2-methylquinoline Derivatives as Potential Antimycobacterial Agents
Shinde, A. D., Ugale, S. R., Nandurkar, Y. M., et al. (2022) · ACS Omega · doi:10.1021/acsomega.2c06245 · Cited by 8
Discovery of napabucasin derivatives for the treatment of tuberculosis
Li, C., Tang, Y., Sang, Z., et al. (2019) · MedChemComm · doi:10.1039/c9md00295b · Cited by 8
Nosiheptide Harbors Potent In Vitro and Intracellular Inhbitory Activities against Mycobacterium tuberculosis
Yu, X., Zhu, R., Geng, Z., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01444-22 · Cited by 7
Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques
Abdelaal, H. F. M., Berube, B. J., Podell, B. K., Harband, M. H., Gary, H. E., Perez-Jaimes, M., Ackart, D. F., Reese, V. A., Larsen, S. E., Pecor, T., et al. (2024) · npj Antimicrobials and Resistance · doi:10.1038/s44259-024-00066-z · Cited by 6
Discovery of Anti‐tubercular Analogues of Bedaquiline with Modified A‐, B‐ and C‐Ring Subunits
Barbaro, L., Nagalingam, G., Triccas, J. A., Tan, L., West, N. P., Priebbenow, D. L., & Baell, J. B. (2022) · ChemMedChem · doi:10.1002/cmdc.202200533 · Cited by 6
Combating Multi-drug Resistant Mycobacterium Species by Efflux Pump Inhibitors: Contemporary Trends
Kumar, G., Mondal, P., Kadam, A., Dhamija, I., Singh, R. P., Nathiya, D., & Kumar, S. (2025) · BIO Integration · doi:10.15212/bioi-2025-0034 · Cited by 11
Exploring the Contribution of Mycobacteria Characteristics in Their Interaction with Human Macrophages
Silva, C., Perdigão, J., Alverca, E., Matos, A., Carvalho, P. A., Portugal, I., & Jordão, L. (2013) · Microscopy and Microanalysis · doi:10.1017/s1431927613001906 · Cited by 6
“Although this approval brought some hope M/XDR-TB remains virtually incurable ~Cohen, 2013!. Acquired drug resistance occurs mainly by mutational events, and taking into account the clonal nature of the Mtb genome, the presence of a beneficial mutation favors bacterial survival and persistence…”
Background
Drug-Resistant Tuberculosis
Khan, F. A., Fox, G. J., & Menzies, D. (2017) · Springer eBooks · doi:10.1007/978-1-4939-0694-9_13 · Cited by 6
Synthesis of 2-(6-substituted quinolin-4-yl)-1-alkoxypropan-2-ol as potential antimycobacterial agents
Shinde, A. D., Thakare, P. P., Nandurkar, Y. M., et al. (2023) · Chemical Papers · doi:10.1007/s11696-023-02741-3 · Cited by 5
“2016; Cohen 2013).”
Synthesis, Biological Evaluation, Molecular Docking Studies and ADMET Prediction of Oxindole-based Hybrids for the Treatment of Tuberculosis
Patel, V. P., Tripathi, R. K. P., & Mandal, S. D. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099353857241022102426 · Cited by 5
Novel Treatments for Drug-Resistant Tuberculosis
Clain, J. M., & Escalante, P. (2016) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s18560 · Cited by 5
Repeated evolution of bedaquiline resistance in Mycobacterium tuberculosis is driven by truncation of mmpR5Preprint
Roberts, L. W., Malone, K. M., Hunt, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.08.519610 · Cited by 5
Recent Developments in Structurally Diverse Anti-Tubercular Drug Molecules and Their Molecular Targets Against Mycobacterium tuberculosis
Alghamdi, S. A., Qusty, N. F., Maulana, A., Ajmal, M., Khan, M., Mahato, A. K., Verma, S., & Asif, M. (2025) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023603257 · Cited by 5
How to Confront the Threat of Ebola? Arguing for Reinforced Efforts to Promote Transnational Solidarity
Fraundorfer, M. (2016) · Global Policy · doi:10.1111/1758-5899.12306 · Cited by 4
Clinical Management of Drug-resistant Mycobacterium tuberculosis Strains: Pathogen-targeted Versus Host-directed Treatment Approaches
Al-Ghafli, H., & Al‐Hajoj, S. (2019) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201019666180731120544 · Cited by 4
First use of bedaquiline in a patient with XDR-TB in Singapore
Chua, A. P.-G., Hoo, G. S. R., Chee, C. B.-E., et al. (2015) · BMJ Case Reports · doi:10.1136/bcr-2015-210961 · Cited by 3
“23 Our results agreed that BDQ-containing regimens contributed to the reduced time to culture conversion and radiological improvements.”
Microbial glycosylation of antitubercular agent chlorflavonin
Ren, J., & Zhan, J. (2023) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2023.09.005 · Cited by 3
Identification of Anti-tubercular Compounds in Marine Organisms from Aotearoa
Dasyam, N. (2014) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17008141 · Cited by 2
Anti-tuberculosis activity in the presence of drug resistance as a rationale for prospect use of thiosonide
Savchenko, A. Y., Burenkov, М. S., Baidin, P. S. B., et al. (2020) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2020-35-1-125-132 · Cited by 2
Lefamulin harbors promising anti-tuberculosis activity against multidrug-resistant Mycobacterium tuberculosis isolates
Wu, J., Ji, Y., Zhang, W., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02250-25 · Cited by 2
Kinetic mechanism and energetics of binding of phosphoryl group acceptors to Mycobacterium tuberculosis cytidine monophosphate kinase
Jaskulski, L., Rosado, L. A., Rostirolla, D. C., et al. (2013) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2013.05.012 · Cited by 2
Pharmacology of Antitubercular Drugs: Challenges and Advances
dos Santos, J. L. (2014) · Biochemistry & Pharmacology Open Access · doi:10.4172/2167-0501.1000e164 · Cited by 2
A structure‐based strategy toward the development of novel candidates for antimycobacterial activity: Synthesis, biological evaluation, and docking study
Li, L., Jin, Y., Wang, B., Yang, Z., Liu, M., Guo, H., Zhang, J., & Lu, Y. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13142 · Cited by 2
Treatment options for MDR- and XDR-TB
Chang, K. C., & Sotgiu, G. (2017) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005616 · Cited by 2
Exploration of Biocompatibility and Toxicity of Nanomaterials in Diagnosis and Treatment of Infectious Diseases
Puvvada, N., Chandu, B., & Panigrahi, P. K. (2025) · Wiley eBooks · doi:10.1002/9781394200559.ch11 · Cited by 2
Cepharanthine as a potential Fis inhibitor enhances Enrofloxacin efficacy against Pasteurella multocida
Xue, Z., Li, P., Wang, X., Inam, M., Dong, H., Liu, D., Wang, D., Wang, J., Jia, Y., Kong, L., et al. (2026) · BMC Microbiology · doi:10.1186/s12866-025-04622-z · Cited by 1
“Currently, the F-type ATP synthase inhibitor bedaquiline has been approved for the treat-ment of Mycobacterium tuberculosis infection [47, 48].”
Drug-Resistant Tuberculosis
Khan, F. A., Fox, G. J., & Menzies, D. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0667-3_13-1 · Cited by 2
Multiomics Integration of Tuberculosis Pathogenesis
Lee, J. J., Sell, P., & Eoh, H. (2023) · Integrated science · doi:10.1007/978-3-031-15955-8_45 · Cited by 1
Clinical Management of Drug-Resistant Tuberculosis in Resource Constrained Settings
Palmero, D., & Ritacco, V. (2013) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s6560 · Cited by 1
Alcaloides aporfínicos con actividad antituberculosa aislados de Ocotea discolor Kunth (Lauraceae)
Murillo, M. C. Á., Melo, L. T. A., Suárez, L. E. C., et al. (2017) · Revista Colombiana de Química · doi:10.15446/rev.colomb.quim.v46n3.62963 · Cited by 1
Bedaquiline: A long but much fruitful wait since seventies
Brashier, D., Khadka, A., Chuki, P., et al. (2014) · International Journal of Pharmacological Research · doi:10.7439/ijpr.v4i4.121
Caracterização da enzima citidina monofosfato quinase (EC 2.7.4.14) de Mycobacterium tuberculosis H37Rv como alvo para o desenvolvimento de drogas para o tratamento da tuberculose
Jaskulski, L. (2013) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Characterization of DD-carboxypeptidase function in mycobacteria: genetic knockout and recombinant protein production
Ismail, Z. S. (2016)
ANTIMICROBIAL ACTIVITY AND REDOX PROPERTY OF Ni(II) COMPLEXES WITH ORTHO- AND META-DIPHENOL DERIVATIVES
Nabebina, K. A., Loginova, N. V., Koval’chuk-Rabchinskaya, T. V., et al. (2020) · RAP Conference Proceedings · doi:10.37392/rapproc.2020.15
Combating antimicrobial resistance : novel targets and anti-infectives development
Chew, A. B. L. (2021) · doi:10.32657/10356/154808
AN INSIGHT INTO PRIVILEGED SCAFFOLDS IN TUBERCULOSIS: DEVELOPMENTAL ASPECTS AND IMPLICATIONS IN DRUG DESIGN
Shinde, R. A., Suvarna, V., & Abhyankar, A. N. (2022) · INDIAN DRUGS · doi:10.53879/id.59.01.13140
MEDICINAL CHEMISTRY ENDEAVORS FOR THE DISCOVERY OF NOVEL TUBERCULOSIS DRUGS
Khonde, L. P., & Jackson, P. (2022) · Medicinal chemistry reviews · doi:10.1021/mc-2022-vol57.ch14
A Comprehensive Investigation of the Interactions between Proteins and Ligands in the Crystal Structures of Mycobacterium Tuberculosis
Nanaware, R. B., Chabukswar, A. R., Tekade, V., Kashid, K., Vidhate, T., & Karmure, R. (2023) · Asian Journal of Chemical Sciences · doi:10.9734/ajocs/2023/v13i5257
Tuberculosis
Hanekom, W. A., Archary, M., & Hawn, T. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-79525-8.00028-7
The design for drug delivery using pili in Mycobacterium tuberculosis
Ghanavi, J., Farnia, P., Aghajani, J., Ayoubi, S., Besharati, S., Farnia, P., & Velayati, A. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21712-8.00020-x
Susceptibility Test Methods: Mycobacteria, Nocardia , and Other Actinomycetes
Brown‐Elliott, B. A., Cirillo, D., Musser, K. A., & Rowlinson, M. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0079
Susceptibility Test Methods: Mycobacteria, Nocardia , and Other Actinomycetes
Brown‐Elliott, B. A., Cirillo, D., Musser, K. A., & Rowlinson, M. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0079
In Vitro Activity of the Triazinyl Diazepine Compound FTSD2 Against Drug-Resistant Mycobacterium tuberculosis Strains
Aranaga, C., Varela, R. E., Falco, A., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18030360
“The introduction of new drugs, such as bedaquiline [2], delamanid [3], and pretomanid [4], as well as the repositioning of existing drugs, such as fluoroquinolones, linezolid, clofazimine, and streptomycin, have provided new options for improving the treatment of drug-resistant tuberculosis.”
Synthesis and evaluation of transvalencin analogues and adenylation inhibitors as antitubercular agents and chemical probes
Nelson, K. M. (2013) · University of Minnesota Digital Conservancy (University of Minnesota)
Mechanochemical Synthesis, Characterization, and Biological Evaluation of N-Cyclohexyl-1,2,3,4-tetrahydro-pyrimidine-5-carboxamide Derivatives
Shah, D., & Patel, A. (2026) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162025603180

Authors: Cohen, J.
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2013-01-11
Volume: 339
Issue: 6116
Pages: 130-130
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.339.6116.130
OpenAlex: W1972806716
Cited by: 166
References: 0
Citations by year: 2026: 2 · 2025: 6 · 2024: 8 · 2023: 11 · 2022: 10 · 2021: 7 · 2020: 9 · 2019: 11 · 2018: 7 · 2017: 17 · 2016: 18 · 2015: 18 · 2014: 18 · 2013: 24
Type: other
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords: tuberculosis, drug approval, FDA approval, tuberculosis treatment, drug development
MeSH terms: Antitubercular Agents, Clinical Trials as Topic, Drug Therapy, Combination, Humans, Mycobacterium tuberculosis, Quinolines, United States, United States Food and Drug Administration, Drug Approval, Tuberculosis, Multidrug-Resistant, Drug Resistance, Multiple, Bacterial, Diarylquinolines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Approval of Novel TB Drug Celebrated—With Restraint

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks